Coronavirus Vaccine Developed. COVID19 Vaccine Launch

New crown vaccine (COVID-19 Vaccine) lays down the first shot, the company behind has developed Ebola Vaccine too

On March 20, according to the Science and Technology Daily report, the new crown virus epidemic developed by Chen Wei's team had previously entered the clinical trial stage and was first injected into volunteers on the 20th.

According to the information from the China Clinical Trial Registry, the first phase of the clinical trial of Chen Wei's team will be conducted from March 16 to December 31, for a period of nine months. The test subjects are healthy adults aged 18 to 60. Volunteers will They were divided into three groups of low dose, medium dose and high dose, with 36 people in each group.

It is reported that the vaccine developed by the academician Chen Wei's team is an adenovirus vector vaccine. Li Bin, a member of the Science Popularization Working Committee of the Chinese Society of Cell Biology and the Shanghai Institute of Immunology of Shanghai Jiaotong University Medical College, introduced in an interview with Shangguan News: Adenovirus vector particles used for vaccines are viruses that are not pathogenic to humans. 

Adenovirus vector is like using an adenovirus

The so-called adenovirus vector is like using an adenovirus as a truck to load some parts of other viruses, namely antigens. Injecting recombinant adenoviruses into the body produces an immune response against these viral antigens. "That is, an adenovirus vaccine can carry several pathogen genes at the same time, and then immunize at the same time.

The vaccine development was carried out by the Chen Wei team in cooperation with Kangsino Biological Co., Ltd. On March 17, Conshino issued an announcement saying that the company and the Institute of Biological Engineering of the Academy of Military Medical Research of the Academy of Military Sciences are jointly developing a new recombinant coronavirus vaccine.

Company was registered in Tianjin Binhai New Area in 2009

According to the official website of Kangsino, the company was registered in Tianjin Binhai New Area in 2009. It is a state-level high-tech enterprise founded by a multinational pharmaceutical company executive team returned to China. In March 2019, Kangsino Bio was listed on the H-shares of the main board of the Hong Kong Stock Exchange.

In January 2020, the company formally submitted and accepted the listing of the science and technology board, and plans to raise funds for the expansion of new vaccine production capacity and research and development of new vaccine products.

Consino's prospectus showed that the company had previously successfully developed an Ebola vaccine. In 2017, Conshino's application for registration of a new drug for recombinant Ebola virus vaccine was successfully approved. The company has also become the third in the world and the first Ebola virus vaccine to enter human clinical practice in Asia. The vaccine is also the same as Academician Chen Wei Cooperative R & D.

The prospectus showed that the company completed the Ebola vaccine of the ad5 virus vector three months after receiving the Ebola strain and was approved in China.

It is worth mentioning that compared to Ebola vaccines developed by international vaccine giants such as Merck, Johnson & Johnson, and GSK, which need to be stored at minus 16 degrees or even minus 70 degrees, compared with Ebola vaccines developed by Conshino, Storage at -8 degrees Celsius is also one of the advantages of the vaccine.

Ebola Success also Paves Way for COVID19 Vaccines

The successful research and development of Ebola vaccine made Concino famous in the vaccine industry, and the experience and methods of developing Ebola vaccine were also used in the development of the new crown vaccine.

Although Conshino has won a lot of attention before, the financial data is not good. Conshino has not been profitable for more than ten years. According to choice data, in 2016, 2017 and 2018, Consino lost 48.85 million, 64.45 million and 138 million, respectively.

COVID19 Vaccine enters the clinical trials in the US

Like Moderna, the company behind the new crown vaccine that entered the clinical trials in the United States, the reason for the huge loss of Concino is also that it has no main business income and has invested huge expenses in research and development.

In 2018, Conshino had revenue of 1.13 million, but R & D investment reached 113 million yuan, an increase of nearly 70% year-on-year.

The related expenses of Kangsino are mainly obtained through financing. Tianyan data shows that as of now, Kangsino has 8 financing processes.

In addition, on January 22, Kangsino issued an announcement saying that the company's science and technology version listing application has been Received the acceptance of the Shanghai Stock Exchange and disclosed the prospectus on February 4. 

It is reported that this time the board of science and technology innovation board, Conshino plans to raise more than 1 billion yuan of funds, will be used for the second phase of the construction of the production base, research and development of vaccines and so on. Among them, the construction of the second phase of the production base is planned to invest 550 million yuan, and the research and development of vaccines is planned to invest 150 million yuan.

Chen Wei, the creator of the new crown vaccine  (COVID19 Vaccine): 26 years of "dancing with the poison" from SARS to Ebola to new crown virus

CCTV News: The reason why New Crown Vaccine came out quickly and entered the clinical stage is not only relying on mature platform technology, but also cannot be separated from the scientific research team's day and night commitment. The New Crown epidemic struck China before the Spring Festival.

Chen Wei and her team immediately started vaccine research and development, quickly completed antigen design and virus packaging during the Spring Festival, and determined that they meet the production technology and quality standards for clinical trial materials. Complete pre-clinical effectiveness and preliminary safety evaluation.

People who are familiar with Chen Wei know that she has one characteristic, which is quickness. Walk fast, speak fast, and work fast. This is a habit developed by Chen Wei for more than 20 years in her research career.

Zhang Xiaopeng, a researcher at the Military Medical Research Institute of the Academy of Military Sciences: She has a keen mind and can handle many things at the same time. I also work in the laboratory every day until eleven or two o'clock, but my current intensity of work still can't keep up with her pace.

Chen Wei, who is extremely popular in her work, was a fashionable girl who loved literature and dance during her school days.

In 1988, Chen Wei graduated from the Department of Chemical Engineering of Zhejiang University and was recommended to pursue a master's degree in biochemical engineering at Tsinghua University because of her outstanding performance.

After graduating, with an ideal for military medicine, Chen Wei decided to put on military uniforms and start her own research career.

In 2003, SARS broke out in various parts of China. Chen Wei's institute was the first to isolate a new coronavirus and identified the culprit of SARS. In order to verify whether interferon for hepatitis C is effective in preventing SARS, she first entered the negative pressure laboratory.

As a rule, people work in a negative pressure laboratory for up to 5 hours at a time. However, in order to compete with the epidemic for time and speed, Chen Wei spent eight or nine hours in the laboratory.

Chen Wei, a member of the Chinese Academy of Engineering, a researcher at the Institute of Military Medicine of the Chinese Academy of Engineering: So we tried not to drink water, eat, or even use the urine of an adult to get wet during the period before we went in. slightly less.

In subsequent large animal experiments and clinics, considering that daily exposure to high concentrations of atypical pneumonia virus was not necessary, Chen Wei and her team were isolated. This picture was taken at that time.

Chen Wei's husband, Ma Yiming: I haven't seen her for a long time. I was informed that day that maybe there will be a shot of your lover in the focus interview today. I waited at home with my son, watching the TV. As soon as her mother came out, my son volunteered to kiss the TV.

At that time, Chen Wei had not seen her son for half a year. She traveled to 83 designated hospitals across the country to guide medication and collect data among high-risk groups.

Academician of the Chinese Academy of Engineering Chen Wei, a researcher at the Academy of Military Medical Sciences of the Academy of Military Sciences: The reporter interviewed me and said that I am afraid to face SARS virus face to face every day? I said at the time that you should do anything in this uniform. This sentence blurted out.

In the end, the "recombinant human interferon omega spray" researched by Chen Wei's team played an important role in protecting 14,000 medical staff.

In 2004, Chen Wei's eyes turned to Ebola virus again.

Chen Wei, a member of the Chinese Academy of Engineering and a researcher at the Military Medical Research Institute of the Academy of Military Sciences: It is a very lethal virus, and we know very little about it. Many of our scientific researchers, including me, asked me what Ebola is and who will use it after you make the Ebola vaccine? I didn't answer these questions, but I couldn't answer them at the time.

Chen Wei did not expect that the struggle with Ebola lasted for ten years. In 2014, a large-scale outbreak of Ebola occurred in West Africa, and it left Africa for the first time to spread to Europe and the Americas. Because the virus mutated, Chen Wei decided to take a trip in person.

Academician of the Chinese Academy of Engineering Chen Wei, a researcher at the Academy of Military Medical Sciences of the Academy of Military Sciences: Although Ebola stepped out of Africa in 2014, its birthplace may be the main region that will be raging in the future.

Soon, the first new genotype vaccine against Ebola was successfully developed. Chen Wei's team obtained the pass for overseas clinical trials, and achieved a "zero" breakthrough in China's independent research and development of vaccines for overseas clinical trials.

In May 2015, Chen Wei's team entered Sierra Leone and started a phase II clinical trial locally.

Facing the unknown danger, Chen Wei took the initiative to walk into the volunteers to check the vaccination situation. In the end, she led the team to a successful clinical trial, setting up a safety barrier for the people in the affected area.

Academician of the Chinese Academy of Engineering Chen Wei, a researcher at the Military Medical Research Institute of the Academy of Military Sciences: At the time, all 48 children had killed their loved ones because of Ebola. This urges us to do it, and really apply scientific research not only to the Chinese, but also to the international community and the African people.

"Dancing with poison" for 26 years, Chen Wei has always kept an eye on all hidden dangers that may affect the country's biological security. Playing chess and taking the initiative in battle is her pursuit as a scientific researcher, and it is her responsibility and responsibility as a soldier. Cast a solid shield for national biosecurity.